These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22213296)

  • 1. Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma.
    Kothari V; Mulherkar R
    Anticancer Res; 2012 Jan; 32(1):121-8. PubMed ID: 22213296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.
    Wang MB; Yip HT; Srivatsan ES
    Laryngoscope; 2001 Jun; 111(6):982-8. PubMed ID: 11404608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro gene silencing by siRNA of cyclin D1 on tongue squamous cell carcinoma cell line resistant to cisplatin].
    Zhou XJ; Zhang ZY; Zhang P; Pan HY; Chen WT; Ye DX
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2006 Nov; 41(11):646-9. PubMed ID: 17331354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
    Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
    Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck.
    Henriksson E; Baldetorp B; Borg A; Kjellen E; Akervall J; Wennerberg J; Wahlberg P
    Acta Oncol; 2006; 45(3):300-5. PubMed ID: 16644573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma.
    Nakashima T; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2000 Aug; 126(8):957-61. PubMed ID: 10922227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of cyclin D1 overexpression in human head and neck cancer cells.
    Nakashima T; Kuratomi Y; Yasumatsu R; Masuda M; Koike K; Umezaki T; Clayman GL; Nakagawa T; Komune S
    Eur Arch Otorhinolaryngol; 2005 May; 262(5):379-83. PubMed ID: 15368064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma.
    Masuda M; Suzui M; Yasumatu R; Nakashima T; Kuratomi Y; Azuma K; Tomita K; Komiyama S; Weinstein IB
    Cancer Res; 2002 Jun; 62(12):3351-5. PubMed ID: 12067972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
    Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.
    Xi S; Dyer KF; Kimak M; Zhang Q; Gooding WE; Chaillet JR; Chai RL; Ferrell RE; Zamboni B; Hunt J; Grandis JR
    J Natl Cancer Inst; 2006 Feb; 98(3):181-9. PubMed ID: 16449678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
    Schedel F; Pries R; Thode B; Wollmann B; Wulff S; Jocham D; Wollenberg B; Kausch I
    Oncol Rep; 2011 Mar; 25(3):763-8. PubMed ID: 21240463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model.
    Sauter ER; Herlyn M; Liu SC; Litwin S; Ridge JA
    Clin Cancer Res; 2000 Feb; 6(2):654-60. PubMed ID: 10690551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of cyclin D1 by small interfering RNA inhibits cell growth and induces apoptosis of laryngeal squamous cell carcinoma.
    Xiao Y; Wang J; Lu J; Liu Y; Wang Y; Gao Y; Jin D
    Am J Otolaryngol; 2011; 32(6):541-6. PubMed ID: 21315488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
    Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
    Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells.
    Suchi K; Fujiwara H; Okamura S; Okamura H; Umehara S; Todo M; Furutani A; Yoneda M; Shiozaki A; Kubota T; Ichikawa D; Okamoto K; Otsuji E
    Anticancer Res; 2011 Jan; 31(1):67-75. PubMed ID: 21273582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
    Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
    Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
    Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
    Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.
    Yoo GH; Lin HS; Iskander AJ; Piechocki MP; Oliver J; Kewson D; Lonardo F; Tainsky MA; Kim HR; Kim H; Ensley JF
    Laryngoscope; 2005 Nov; 115(11):1938-46. PubMed ID: 16319602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck.
    Akervall J; Kurnit DM; Adams M; Zhu S; Fisher SG; Bradford CR; Carey TE
    Acta Otolaryngol; 2004 Sep; 124(7):851-7. PubMed ID: 15484403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.